205 related articles for article (PubMed ID: 34767586)
21. Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.
Kimura M; Bañez LL; Gerber L; Qi J; Tsivian M; Freedland SJ; Satoh T; Polascik TJ; Baba S; Moul JW
J Sex Med; 2012 Apr; 9(4):1174-81. PubMed ID: 22188861
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience.
Leyh-Bannurah SR; Dell'Oglio P; Zaffuto E; Briganti A; Schiffmann J; Pompe RS; Tilki D; Heinzer H; Graefen M; Karakiewicz PI; Budäus L
Eur Urol Focus; 2019 Jul; 5(4):568-576. PubMed ID: 29129756
[TBL] [Abstract][Full Text] [Related]
23. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
24. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
[TBL] [Abstract][Full Text] [Related]
25. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
26. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
27. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
28. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.
Schiffmann J; Salomon G; Tilki D; Budäus L; Karakiewicz PI; Leyh-Bannurah SR; Pompe RS; Haese A; Heinzer H; Huland H; Graefen M; Tennstedt P
Urol Oncol; 2017 May; 35(5):243-249. PubMed ID: 28161322
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer.
Kang HW; Jung HD; Lee JY; Kwon JK; Jeh SU; Cho KS; Ham WS; Choi YD
Asian J Androl; 2016; 18(3):480-4. PubMed ID: 26178393
[TBL] [Abstract][Full Text] [Related]
30. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients.
Xu H; Zhu Y; Dai B; Ye DW
Asian J Androl; 2018; 20(6):551-554. PubMed ID: 30027928
[TBL] [Abstract][Full Text] [Related]
31. Specific spatial distribution patterns of tumor foci are associated with a low risk of biochemical recurrence in pT2pN0R0 prostate cancer.
Eminaga O; Abbas M; Bettendorf O; Semjonow A
World J Urol; 2021 May; 39(5):1499-1507. PubMed ID: 32591903
[TBL] [Abstract][Full Text] [Related]
32. Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.
Llukani E; Lepor H
BJU Int; 2017 Oct; 120(4):505-510. PubMed ID: 28220652
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
34. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
35. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
37. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
[TBL] [Abstract][Full Text] [Related]
38. Race, tumor location, and disease progression among low-risk prostate cancer patients.
Mygatt JG; Cullen J; Streicher SA; Kuo HC; Chen Y; Young D; Gesztes W; Williams G; Conti G; Porter C; Stroup SP; Rice KR; Rosner IL; Burke A; Sesterhenn I
Cancer Med; 2020 Mar; 9(6):2235-2242. PubMed ID: 31965751
[TBL] [Abstract][Full Text] [Related]
39. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.
Lee H; Jeong SJ; Hong SK; Byun SS; Lee SE; Oh JJ
World J Urol; 2016 Jun; 34(6):821-7. PubMed ID: 26449784
[TBL] [Abstract][Full Text] [Related]
40. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
Mazzone E; Gandaglia G; Ploussard G; Marra G; Valerio M; Campi R; Mari A; Minervini A; Serni S; Moschini M; Marquis A; Beauval JB; van den Bergh R; Rahota RG; Soeterik T; Roumiguiè M; Afferi L; Zhuang J; Guo H; Mattei A; Gontero P; Cucchiara V; Stabile A; Fossati N; Montorsi F; Briganti A
Eur Urol; 2022 Feb; 81(2):193-203. PubMed ID: 34399996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
